LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-231 | Mitoxantrone | 10.0 | uM | LJP5 | 1 | C19 | 72 | hr | 1235 | 96 | 4513 | 0.0213 | -0.3478 |
| MDA-MB-231 | Mitoxantrone | 10.0 | uM | LJP5 | 2 | C19 | 72 | hr | 1235 | 75 | 4513 | 0.0166 | -0.3542 |
| MDA-MB-231 | Mitoxantrone | 10.0 | uM | LJP5 | 3 | C19 | 72 | hr | 1235 | 88 | 4513 | 0.0195 | -0.3502 |
| MDA-MB-231 | Mitoxantrone | 10.0 | uM | LJP6 | 1 | C19 | 72 | hr | 1235 | 102 | 4513 | 0.0226 | -0.3460 |
| MDA-MB-231 | Mitoxantrone | 10.0 | uM | LJP6 | 2 | C19 | 72 | hr | 1235 | 120 | 4513 | 0.0266 | -0.3405 |
| MDA-MB-231 | Mitoxantrone | 10.0 | uM | LJP6 | 3 | C19 | 72 | hr | 1235 | 104 | 4513 | 0.0230 | -0.3454 |
| MDA-MB-231 | MK2206 | 10.0 | uM | LJP6 | 1 | F01 | 72 | hr | 1235 | 1437 | 4513 | 0.3184 | 0.0613 |
| MDA-MB-231 | MK2206 | 10.0 | uM | LJP6 | 2 | F01 | 72 | hr | 1235 | 2188 | 4513 | 0.4848 | 0.2905 |
| MDA-MB-231 | MK2206 | 10.0 | uM | LJP6 | 3 | F01 | 72 | hr | 1235 | 1943 | 4513 | 0.4305 | 0.2157 |
| MDA-MB-231 | Neratinib | 10.0 | uM | LJP5 | 1 | A13 | 72 | hr | 1235 | 1079 | 4513 | 0.2391 | -0.0479 |
| MDA-MB-231 | Neratinib | 10.0 | uM | LJP5 | 2 | A13 | 72 | hr | 1235 | 801 | 4513 | 0.1775 | -0.1327 |
| MDA-MB-231 | Neratinib | 10.0 | uM | LJP5 | 3 | A13 | 72 | hr | 1235 | 513 | 4513 | 0.1137 | -0.2206 |
| MDA-MB-231 | Nilotinib | 10.0 | uM | LJP5 | 1 | N13 | 72 | hr | 1235 | 951 | 4513 | 0.2107 | -0.0869 |
| MDA-MB-231 | Nilotinib | 10.0 | uM | LJP5 | 2 | N13 | 72 | hr | 1235 | 1006 | 4513 | 0.2229 | -0.0702 |
| MDA-MB-231 | Nilotinib | 10.0 | uM | LJP5 | 3 | N13 | 72 | hr | 1235 | 1057 | 4513 | 0.2342 | -0.0546 |
| MDA-MB-231 | Nintedanib | 10.0 | uM | LJP6 | 1 | H01 | 72 | hr | 1235 | 803 | 4513 | 0.1779 | -0.1321 |
| MDA-MB-231 | Nintedanib | 10.0 | uM | LJP6 | 2 | H01 | 72 | hr | 1235 | 945 | 4513 | 0.2094 | -0.0888 |
| MDA-MB-231 | Nintedanib | 10.0 | uM | LJP6 | 3 | H01 | 72 | hr | 1235 | 1551 | 4513 | 0.3436 | 0.0961 |
| MDA-MB-231 | NU7441 | 10.0 | uM | LJP5 | 1 | C07 | 72 | hr | 1235 | 1219 | 4513 | 0.2701 | -0.0052 |
| MDA-MB-231 | NU7441 | 10.0 | uM | LJP5 | 2 | C07 | 72 | hr | 1235 | 1209 | 4513 | 0.2679 | -0.0082 |
| MDA-MB-231 | NU7441 | 10.0 | uM | LJP5 | 3 | C07 | 72 | hr | 1235 | 1159 | 4513 | 0.2568 | -0.0235 |
| MDA-MB-231 | Dactolisib | 10.0 | uM | LJP5 | 1 | M13 | 72 | hr | 1235 | 1621 | 4513 | 0.3591 | 0.1175 |
| MDA-MB-231 | Dactolisib | 10.0 | uM | LJP5 | 2 | M13 | 72 | hr | 1235 | 1599 | 4513 | 0.3543 | 0.1108 |
| MDA-MB-231 | Dactolisib | 10.0 | uM | LJP5 | 3 | M13 | 72 | hr | 1235 | 1716 | 4513 | 0.3802 | 0.1465 |
| MDA-MB-231 | NVP-TAE684 | 10.0 | uM | LJP6 | 1 | K13 | 72 | hr | 1235 | 378 | 4513 | 0.0837 | -0.2618 |